Lulizumab pegol (

INN Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway. Before the advent of motorized transportation, they also provided accomm ...

; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol
''

American Medical Association The American Medical Association (AMA) is an American professional association and lobbying group of physicians and medical students. This medical association was founded in 1847 and is headquartered in Chicago, Illinois. Membership was 271,660 ...

''. This drug was developed by

Bristol-Myers Squibb The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consist ...

References

Monoclonal antibodies Drugs developed by Bristol Myers Squibb {{monoclonal-antibody-stub